Table 2.

Univariate analysis for disease-free and overall survival

Variable	No. of patients	Median DFS (mo)	p-valuea)	Median OS (mo)	p-valuea)
Age (yr)			0.6466		0.4041
< 65	34	15.4		34.7
≥ 65	28	15.0		50.0
Gender			0.1063		0.0432
Male	31	10.5		23.8
Female	31	22.5		61.3
Performance (ECOG)			0.2269		0.3790
0-1	58	15.9		37.5
2	4	7.6		10.8
SA invasion			0.0123		0.1084
Yes	36	11.0		27.6
No	26	49.2		68.6
SV invasion			0.1723		0.5081
Yes	43	15.4		37.5
No	19	49.2		68.6
Tumor size (cm)			0.2070		0.6161
< 3	27	17.3		37.5
≥ 3	35	12.4		45.8
RM involvement			0.0002		0.0002
Yes	11	8.2		16.3
No	51	18.4		50.0
Lymph node metastasis			0.1115		0.1994
Yes	33	10.4		34.7
No	29	27.6		50.0
Angiolymphatic invasion			0.0503		0.0138
Yes	18	8.2		13.8
No	44	18.2		61.3
Venous invasion			0.0008		0.0206
Yes	16	10.4		18.5
No	46	22.5		54.7
Perineural invasion			0.0912		0.4778
Yes	48	12.1		34.7
No	12	NR		54.7
RT dose (Gy)			0.3948		0.1978
< 50	13	10.4		22.0
≥ 50	49	17.3		54.7
Op-RT duration (day)			0.7631		0.9182
< 45	32	18.4		37.5
≥ 45	30	11.0		50.0
Concurrent chemotherapy			0.8668		0.8968
Gemcitabine	16	10.1		17.9
Others	46	16.5		37.5

DFS, disease-free survival; OS, overall survival; ECOG, Eastern Cooperative Oncology Group; SA, splenic artery; SV, splenic vein; RM, resection margin; NR, not reached; RT, radiotherapy; Op, operation.

^a)Log-rank test.